blood coagulation factors

Summary

Summary: Endogenous substances, usually proteins, that are involved in the blood coagulation process.

Top Publications

  1. ncbi Activation of endothelial cell protease activated receptor 1 by the protein C pathway
    Matthias Riewald
    Department of Immunology, C204, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 296:1880-2. 2002
  2. ncbi Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients
    Pratima Chowdary
    Departments of Haematology Intensive Care Medicine, University Hospital of Wales and University of Wales College of Medicine, Heath Park, Cardiff, UK
    Br J Haematol 125:69-73. 2004
  3. ncbi Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). The structural and functional conservation in human, bovine, and murine EPCR
    K Fukudome
    Howard Hughes Medical Institute, University of Oklahoma Health Sciences Center, Oklahoma City
    J Biol Chem 270:5571-7. 1995
  4. ncbi Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection
    Michael R Sutherland
    Canadian Blood Services, Research and Development Department, University of British Columbia, Centre for Blood Research, Vancouver, BC, Canada
    Blood 119:3638-45. 2012
  5. ncbi The genetics of haemostasis: a twin study
    M de Lange
    Twin Research and Genetic Epidemiology Unit, St Thomas' Hospital, London, UK
    Lancet 357:101-5. 2001
  6. ncbi Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C
    Clemens Feistritzer
    Division of General Internal Medicine, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria
    J Allergy Clin Immunol 112:375-81. 2003
  7. pmc A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model
    Jorge G Ganopolsky
    W M Keck Center for Transgene Research, Department of Chemistry and Biochemistry, 434 Stepan Hall of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
    Am J Pathol 165:1433-46. 2004
  8. ncbi A model for the stoichiometric regulation of blood coagulation
    Matthew F Hockin
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, Vermont 05405, USA
    J Biol Chem 277:18322-33. 2002
  9. ncbi Role of tissue factor in hemostasis, thrombosis, and vascular development
    Nigel Mackman
    The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, Calif 92037, USA
    Arterioscler Thromb Vasc Biol 24:1015-22. 2004
  10. ncbi Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity
    Olivier M Vanakker
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    J Invest Dermatol 127:581-7. 2007

Detail Information

Publications320 found, 100 shown here

  1. ncbi Activation of endothelial cell protease activated receptor 1 by the protein C pathway
    Matthias Riewald
    Department of Immunology, C204, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 296:1880-2. 2002
    ..Thus, the prototypical thrombin receptor is the target for EPCR-dependent APC signaling, suggesting a role for this receptor cascade in protection from sepsis...
  2. ncbi Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients
    Pratima Chowdary
    Departments of Haematology Intensive Care Medicine, University Hospital of Wales and University of Wales College of Medicine, Heath Park, Cardiff, UK
    Br J Haematol 125:69-73. 2004
    ....
  3. ncbi Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). The structural and functional conservation in human, bovine, and murine EPCR
    K Fukudome
    Howard Hughes Medical Institute, University of Oklahoma Health Sciences Center, Oklahoma City
    J Biol Chem 270:5571-7. 1995
    ..Cloning of the murine and bovine homologue of EPCR will facilitate in vivo and in vitro studies of the role of EPCR in the protein C pathway...
  4. ncbi Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection
    Michael R Sutherland
    Canadian Blood Services, Research and Development Department, University of British Columbia, Centre for Blood Research, Vancouver, BC, Canada
    Blood 119:3638-45. 2012
    ..These results show that HSV1 surface cofactors promote cellular PAR2-mediated infection, indicating a novel mode by which pathogens exploit the initiation phase of the host hemostatic system...
  5. ncbi The genetics of haemostasis: a twin study
    M de Lange
    Twin Research and Genetic Epidemiology Unit, St Thomas' Hospital, London, UK
    Lancet 357:101-5. 2001
    ..Our results stress the importance of research into the genetic regulation of proteins involved in haemostasis and atherothrombotic disorders, including myocardial infarction and stroke...
  6. ncbi Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C
    Clemens Feistritzer
    Division of General Internal Medicine, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria
    J Allergy Clin Immunol 112:375-81. 2003
    ..Eosinophil infiltration is a characteristic feature of allergic inflammation. Allergic responses are associated with local activation of the coagulation pathway and accumulation of fibrin...
  7. pmc A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model
    Jorge G Ganopolsky
    W M Keck Center for Transgene Research, Department of Chemistry and Biochemistry, 434 Stepan Hall of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
    Am J Pathol 165:1433-46. 2004
    ..Thus, the hemodynamic role of PC during sepsis is of critical importance to the outcome of the disease...
  8. ncbi A model for the stoichiometric regulation of blood coagulation
    Matthew F Hockin
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, Vermont 05405, USA
    J Biol Chem 277:18322-33. 2002
    ..A comparison of the model with empirical laboratory data illustrates that most experimentally observable parameters are captured, and the pathology that results in enhanced or deficient thrombin generation is accurately described...
  9. ncbi Role of tissue factor in hemostasis, thrombosis, and vascular development
    Nigel Mackman
    The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, Calif 92037, USA
    Arterioscler Thromb Vasc Biol 24:1015-22. 2004
    ..This review focuses on the roles of TF in hemostasis, thrombosis, and vascular development...
  10. ncbi Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity
    Olivier M Vanakker
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    J Invest Dermatol 127:581-7. 2007
    ..These findings all support the hypothesis that the disorder indeed represents a separate clinical and genetic entity, the molecular background of which remains to be unraveled...
  11. ncbi Expression and function of the endothelial protein C receptor in human neutrophils
    Daniel H Sturn
    Department of Internal Medicine, University of Innsbruck, Austria
    Blood 102:1499-505. 2003
    ..Inhibitory effects of these components of the protein C pathway on neutrophil function may play a role in the protein C-based treatment of severe sepsis...
  12. ncbi Endothelial cell protein C receptor plays an important role in protein C activation in vivo
    F B Taylor
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Blood 97:1685-8. 2001
    ..The results indicate that EPCR plays a major role in protein C activation and suggest that defects in the EPCR gene might contribute to increased risk of thrombosis...
  13. ncbi Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis
    Karim Brohi
    Department of Surgery, The Royal London Hospital, London, United Kingdom
    J Trauma 64:1211-7; discussion 1217. 2008
    ..The coagulopathy has recently been associated with systemic activation of the protein C pathway. This study was designed to characterize the thrombotic, coagulant and fibrinolytic derangements of trauma-induced shock...
  14. ncbi Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains
    R E Simmonds
    Department of Haematology, Imperial College School of Medicine, London, UK
    Blood 94:632-41. 1999
    ..1 from crystal structures. These findings suggest that the EPCR folds with a beta-sheet platform supporting two alpha-helical regions collectively forming a potential binding pocket for protein C/activated protein C...
  15. ncbi Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series
    C Escuriola Ettingshausen
    Centre for Paediatrics, Clinic III, Comprehensive Care Center for Thrombosis and Hemostasis, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, Frankfurt am Main, Germany
    Haemophilia 16:90-100. 2010
    ..The only adverse event involved venous access. Therefore early long-term FEIBA prophylaxis is valuable in controlling bleeding and preserving joint integrity in young patients failing ITI...
  16. ncbi Activated protein C inhibits the expression of platelet-derived growth factor in the lung
    Shino Shimizu
    Department of Molecular Pathobiology, Mie University School of Medicine, Tsu City, Japan
    Am J Respir Crit Care Med 167:1416-26. 2003
    ..In brief, this study describes a novel biological function of activated protein C that may further explain its inhibitory activity on lung inflammation and fibrosis...
  17. ncbi Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation
    James H Finigan
    Center for Translational Respiratory Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland 21224, USA
    J Biol Chem 280:17286-93. 2005
    ..These data suggest that novel EPCR ligation and S1P1 transactivation results in EC cytoskeletal rearrangement and barrier protection, components potentially critical to the improved survival of APC-treated patients with severe sepsis...
  18. ncbi Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury
    Oliver Grottke
    Department of Anesthesiology, RWTH Aachen University Hospital, Aachen, Germany
    Blood 118:1943-51. 2011
    ..In conclusion, 35 IU/kg PCC safely improved coagulation and attenuated blood loss. However, the higher dose of PCC (50 IU/kg) appeared to increase the risk of thromboembolism and disseminated intravascular coagulation...
  19. ncbi Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors
    Cindy Leissinger
    Louisiana Center for Bleeding and Clotting Disorders, Tulane University, New Orleans, LA, USA
    N Engl J Med 365:1684-92. 2011
    ..Effective strategies to prevent bleeding in such patients have not yet been established...
  20. pmc Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men
    S G Wannamethee
    Department of Primary Care and Population Health, UCL Medical School, Royal Free Campus, London NW3 2PF, UK
    J Thromb Haemost 7:1605-11. 2009
    ....
  21. pmc Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease
    Kazumasa Yamagishi
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA
    J Atheroscler Thromb 17:402-9. 2010
    ..To examine whether plasma levels of coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin are associated with coronary heart disease (CHD) in a prospective case-cohort study...
  22. pmc Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition
    Anetta Undas
    Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
    Thromb Haemost 104:224-30. 2010
    ..Simulations of thrombin formation suggest that blood plasma composition, i.e. a marked increase in FVIII, somewhat counterbalanced by free TFPI, contributes to the prothrombotic phenotype in RA patients...
  23. ncbi Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function
    P C Liaw
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    J Biol Chem 275:5447-52. 2000
    ..8 +/- 0.6%. sEPCR also stimulated the amidolytic activity of APC toward synthetic substrates. We conclude that sEPCR binding to APC blocks phospholipid interaction and alters the active site of APC...
  24. ncbi Thrombogenicity of prothrombin complex concentrates
    M Kohler
    Department of Transfusion Medicine, University of Gottingen, Germany
    Thromb Res 95:S13-7. 1999
    ..The declining incidence and the recent cluster of fatal thromboembolic adverse events in Germany with one brand of PCC is strong evidence for the crucial role of the quality of PCC in the occurrence of thromboembolic adverse effects...
  25. ncbi Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition
    K Brummel-Ziedins
    Department of Biochemistry, University of Vermont, VT 05446, USA
    J Thromb Haemost 6:104-10. 2008
    ..We investigated whether thrombin generation based on circulating coagulation protein levels, could distinguish between acute and stable coronary artery disease (CAD)...
  26. ncbi Coagulation parameters and plasma total homocysteine levels in Behcet's disease
    Yun Jong Lee
    Department of Internal Medicine, Clinical Research Institute, College of Medicine, Seoul National University, Seoul, Republic of Korea
    Thromb Res 106:19-24. 2002
    ..857, p<0.01). Therefore, coagulation abnormality did not contribute to thrombotic complications, and higher levels of homocysteine may play a role in the hypercoagulablity of BD patients...
  27. pmc The plasma hemostatic proteome: thrombin generation in healthy individuals
    K Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 3:1472-81. 2005
    ..The range of plasma concentrations of hemostatic analytes in the population is wide. In this study these components of blood coagulation phenotype are integrated in an attempt to predict clinical risk...
  28. ncbi Coagulation factors and the protein C system as determinants of thrombin generation in a normal population
    A W J H Dielis
    Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    J Thromb Haemost 6:125-31. 2008
    ..Thrombin generation is a powerful tool to probe overall plasma coagulability...
  29. ncbi Postpartum acquired hemophilia (factor VIII inhibitors): a case report and review of the literature
    S A Shobeiri
    Louisiana State University Health Sciences Center, Department of Obstetrics and Gynecology, New Orleans 70112, USA
    Obstet Gynecol Surv 55:729-37. 2000
    ..The literature concerning acquired hemophilia is reviewed, and new therapeutic medical advances are emphasized...
  30. ncbi VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors
    Reidar Wallin
    Departments of Internal Medicine and Biochemistry, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157
    Vitam Horm 78:227-46. 2008
    ..has opened new opportunities to understand warfarin resistance and biosynthesis of vitamin K-dependent blood coagulation factors and other members of this protein family...
  31. pmc The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis
    Margarita Pérez-Casal
    Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK
    Crit Care 15:R195. 2011
    ..We hypothesised that APC on these circulating MPs activate endothelial protease-activated receptor 1 (PAR1) to induce anti-apoptotic and anti-inflammatory properties that can improve patient outcome...
  32. ncbi Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors
    C A Leissinger
    Section of Hematology Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Haemophilia 13:249-55. 2007
    ..This case series demonstrates that routine aPCC administration may be used safely and effectively to reduce the occurrence of bleeding episodes and to maintain or improve clinical joint status in some patients...
  33. ncbi Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma
    O M Theusinger
    Institute of Anaesthesiology, University Hospital Zurich, Zurich, Switzerland
    Br J Anaesth 106:505-11. 2011
    ..Indications, efficacy, and safety of plasma products are highly debated. We compared the concentrations of haemostatic proteins and cytokines in solvent/detergent-treated plasma (SDP) and fresh-frozen plasma (FFP)...
  34. ncbi Thrombin generation: phenotypic quantitation
    K E Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 2:281-8. 2004
    ..Overall, these data suggest that thrombin generated in whole blood exclusively by tissue factor stimulation can be used as an integrative phenotypic marker to determine an individual's response to a tissue factor challenge...
  35. ncbi Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin
    W Li
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    J Thromb Haemost 3:1351-9. 2005
    ..The Tie2-EPCR animals also generate more APC upon lipopolysaccharide (LPS) challenge and have a survival advantage. These results reveal that overexpression of EPCR can protect animals against thrombotic or septic challenge...
  36. ncbi Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study
    R Demeyere
    Department of Anaesthesiology, University Hospital Gasthuisberg, Leuven, Belgium
    Vox Sang 99:251-60. 2010
    ..Fresh frozen plasma (FFP) and prothrombin complex concentrates (PCC) reverse oral anticoagulants. We compared PCC and FFP intraoperative administration in patients undergoing heart surgery with cardiopulmonary bypass (CPB)...
  37. ncbi Treating coagulopathy in trauma patients
    Ray Armand
    Department of Pathology, University of Maryland Medical Center, Baltimore, MD 21201, USA
    Transfus Med Rev 17:223-31. 2003
    ..It is exacerbated by dilution, acidosis, and hypothermia. Hemorrhage control, warming, and appropriate blood product support are lifesaving. Further improvements in hemorrhage control will save additional lives and resources...
  38. ncbi Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability
    M S Freeman
    Academic Unit of Molecular Vascular Medicine, The General Infirmary at Leeds, University of Leeds, Leeds, UK
    Arterioscler Thromb Vasc Biol 22:506-10. 2002
    ..The impact of certain well-characterized polymorphisms to the heritability is small in this population of healthy families, indicating the need to localize new genes influencing hemostatic factor levels...
  39. ncbi Lepirudin blunts endotoxin-induced coagulation activation
    T Pernerstorfer
    Department of Clinical Pharmacology TARGET, Vienna General Hospital, Wien, Austria
    Blood 95:1729-34. 2000
    ..Results from this trial provide a rationale for a randomized clinical trial on the efficacy of lepirudin in DIC. (Blood. 2000;95:1729-1734)..
  40. ncbi The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma
    Petra Innerhofer
    Clinic of Anaesthesiology and Intensive Care Medicine, Innsbruck Medical University, Innsbruck, Austria
    Injury 44:209-16. 2013
    ..FFP and coagulation factor concentrates are used to correct trauma-induced coagulopathy (TIC). However, data on coagulation profiles investigating effects of therapy are scarce...
  41. pmc Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity
    Dmitry M Shayakhmetov
    Division of Medical Genetics, Department of Medicine, Department of Pathology, University of Washington, Seattle, WA 98195, USA
    J Virol 79:7478-91. 2005
    ..It also provides a rationale for novel strategies to target adenovirus vector to specific tissues and to reduce virus-associated toxicity after systemic application...
  42. ncbi Laboratory markers in the diagnosis of venous thromboembolism
    Joseph A Caprini
    Department of Surgery, Evanston Northwestern Healthcare, Burch 104, 2650 Ridge Ave, Evanston, Ill 60201, USA
    Circulation 109:I4-8. 2004
    ..Often, lifelong anticoagulation may be needed as these patients and family members may need testing before taking birth control pills or hormonal replacement...
  43. ncbi Rotational thromboelastometry analysis and management of life-threatening haemorrhage in isolated craniofacial injury
    Alberto Grassetto
    UOC Anestesia e Rianimazione, Dipartimento di Emergenza Urgenza, Ospedale dell Angelo di Mestre, Venice, Italy
    Blood Coagul Fibrinolysis 23:551-5. 2012
    ..This report highlights the potential for using ROTEM to guide treatment with fibrinogen and prothrombin complex concentrates in the presence of profuse multifocal bleeding and severe coagulopathy...
  44. ncbi The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series
    L A Valentino
    RUSH Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL 60612 3833, USA
    Haemophilia 15:733-42. 2009
    ..Prophylaxis with APCC can reduce haemorrhages and halt further joint deterioration in patients with haemophilia and inhibitors...
  45. ncbi Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors
    H M Spronk
    Department of Pediatrics, Sainte Therese Hospital, Beirut, Lebanon
    Blood 96:3650-2. 2000
    ..In 50 nonrelated normal subjects, the mutation was not found. This is the second time a missense mutation in the gamma-glutamyl carboxylase gene is described that has serious impact on normal hemostasis...
  46. ncbi Coagulation factor levels in neurosurgical patients with mild prolongation of prothrombin time: effect on plasma transfusion therapy
    Karen Matevosyan
    Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Neurosurg 114:3-7. 2011
    ..Therefore, the authors performed relevant coagulation factor assays to assess coagulopathy in such patients. They also compared plasma transfusion practices in their hospital before and after the study...
  47. ncbi Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study
    B Siegerink
    Department of Clinical Epidemiology, LUMC, Leiden, The Netherlands
    Circulation 122:1854-61. 2010
    ..This study aims to determine the risks of arterial thrombosis conferred by increased activation of intrinsic coagulation proteins in young women and the effect of oral contraceptive use on this association...
  48. ncbi Dysfunction of endothelial protein C activation in severe meningococcal sepsis
    S N Faust
    Department of Paediatrics, Imperial College School of Medicine at St Mary's Hospital, London, United Kingdom
    N Engl J Med 345:408-16. 2001
    ..CONCLUSIONS: In severe meningococcal sepsis, protein C activation is impaired, a finding consistent with down-regulation of the endothelial thrombomodulin-endothelial protein C receptor pathway...
  49. ncbi Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy
    N Khorsand
    Department of Hospital Pharmacy, Medical Centre Haaglanden, The Hague, The Netherlands
    Transfus Med 21:116-23. 2011
    ..In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used...
  50. ncbi Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia
    Markus Honickel
    Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany
    Thromb Haemost 106:724-33. 2011
    ..Furthermore, the impact and safety of PCC application can be monitored through thrombin generation and thromboelastometry under hypothermia...
  51. ncbi Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis
    Masahiro Takeyama
    Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
    Blood Coagul Fibrinolysis 18:1-7. 2007
    ..Careful attention to the anticoagulant effect as well as thrombogenicity of PCC is required. Monitoring therapy using such as ROTEM analysis could be highly informative...
  52. ncbi Heparin-induced effects of prothrombin complex concentrates in thromboelastometry
    Gisela Scharbert
    Department of Special Anesthesiology and Pain Management, General Intensive Care and Pain Control, Vienna Medical University, 1090, Vienna, Waehringer Guertel 18 20, Austria
    Wien Klin Wochenschr 124:320-5. 2012
    ..In an in vitro experiment, we compared the PCC preparation used in the experiments of Takeyama with a high heparin content to a new heparin-free PCC preparation...
  53. ncbi Methodological issues with coagulation testing in patients with liver disease
    T Lisman
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 4:2061-2. 2006
  54. pmc Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity
    Benny Sørensen
    Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Department of Haematology and Oncology, Guy s and St Thomas Hospital and NHS Trust Foundation, King s College London School of Medicine, 1st Floor, North Wing, St Thomas Hospital, Westminster Bridge Road, London SE1 7EH, UK
    Crit Care 15:201. 2011
    ..The risk of a thrombotic complication due to treatment with PCCs should be weighed against the need for rapid and effective correction of coagulopathy...
  55. ncbi Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor. Implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor
    P C Liaw
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
    J Biol Chem 276:8364-70. 2001
    ..These studies are also the first to identify the protein C/APC binding region of EPCR and may provide useful information about molecular defects in EPCR that could contribute to cardiovascular disease susceptibility...
  56. ncbi Blood coagulation factors in the black headed vulture (Coragyps atratus), a potential animal model for the study of haemostasis
    Jesus Weir-M
    Instituto Hematológico de Occidente, Laboratorio de Coagulación y Hemostasia, lado Maternidad Castillo Plaza, Av 20, Maracaibo, Edo Zulia, Maracaibo, Venezuela
    Thromb Res 113:269-73. 2004
  57. ncbi Haemostasis in normal pregnancy: a balancing act?
    V A Holmes
    Department of Medicine, Queen s University Belfast, Belfast BT12 6BW, UK
    Biochem Soc Trans 33:428-32. 2005
    ..This balance is maintained, at least partly, by an increase in fibrinolytic activity, but decreases in other factors such as factor XI and monocyte tissue factor expression may also serve to counterbalance procoagulant changes...
  58. ncbi The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C
    L M Regan
    Howard Hughes Medical Institute, Oklahoma City, Oklahoma 73104, USA
    J Biol Chem 272:26279-84. 1997
    ..These data suggest that the Gla domain of protein C is responsible for much of the binding energy and specificity of the protein C-EPCR interaction...
  59. ncbi Prothrombin complex concentrates for urgent anticoagulation reversal in patients with intracranial haemorrhage
    D Imberti
    Ospedale Civile, Piacenza, Italy
    Pathophysiol Haemost Thromb 36:259-65. 2008
    ..Prothrombin complex concentrates (PCCs) produce a rapid and effective reversal of OAT effects, but little evidence exists on their efficacy and safety in the management of ICH in patients on OAT...
  60. ncbi Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA
    S Gallistl
    Ludwig Boltzmann Research Institute for Pediatric Hemostasis and Thrombosis, University of Graz, Austria
    Blood Coagul Fibrinolysis 13:653-5. 2002
    ..Changes of factor IX or factor X concentrations showed neither an effect on the TP nor on lag phases. Our study demonstrates that thrombin generation in the presence of FEIBA mainly depends on prothrombin...
  61. ncbi Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates
    Catherine N Bagot
    Department of Haematology, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Thromb Haemost 98:1141-2. 2007
  62. pmc Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor
    Laurent O Mosnier
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Biochem J 373:65-70. 2003
    ..Consistent with this implication, both protease-activated receptor-1 (PAR-1) and endothelial cell protein C receptor (EPCR) were required for the anti-apoptotic effects of activated protein C...
  63. ncbi Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis
    W C Aird
    Harvard Medical School and Beth Israel Medical School, Boston, MA 02215, USA
    Crit Care Med 29:S28-34; discussion S34-5. 2001
    ..To examine the role of vascular bed-specific pathways in determining the hemostatic phenotype in sepsis...
  64. ncbi The cytoprotective protein C pathway
    Laurent O Mosnier
    Department of Molecular and Experimental Medicine MEM 180, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, USA
    Blood 109:3161-72. 2007
    ....
  65. pmc Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
    David Bruce
    Department of Haematology, Derriford Hospital, Brest Road, Plymouth, Devon PL6 8DH, UK
    Crit Care 12:R105. 2008
    ..We investigated the use of a prothrombin complex concentrate (PCC; Beriplex P/N, CSL Behring, Marburg, Germany) to treat severe bleeding in a variety of settings: cardiac surgery, warfarin therapy and other surgery...
  66. pmc Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding
    Kerstin S Schick
    Department of Surgery, University of Munich Grosshadern, Marchioninistrasse 15 81377 Munich, Germany
    Crit Care 13:R191. 2009
    ..The aim of this study was to retrospectively evaluate the efficacy of prothrombin complex concentrates in the surgical setting...
  67. ncbi Haemostatic changes in pregnancy
    Benjamin Brenner
    Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, P O Box 9602, Haifa 31096, Israel
    Thromb Res 114:409-14. 2004
    ..Disruption of anticoagulant mechanisms, for example, autoantibodies, to annexin V may increase pregnancy complications in patients with antiphospholipid antibodies (APLA)...
  68. pmc Warfarin reversal
    J P Hanley
    Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne UK
    J Clin Pathol 57:1132-9. 2004
    ..This review discusses the current approaches to warfarin reversal in clinical practice. The development of a uniform approach to warfarin reversal in the Northern Region is described...
  69. ncbi A retrospective postlicensure survey of FEIBA efficacy and safety
    D Dimichele
    New York Presbyterian Weill Cornell Center, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    Haemophilia 12:352-62. 2006
    ..Results indicated that FEIBA was safe and effective in acute, surgical, and prophylactic treatment settings, supporting the utility of FEIBA as a treatment option for patients with inhibitors. However, prospective studies are advised...
  70. ncbi Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction
    Cindy A Leissinger
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Am J Hematol 77:187-93. 2004
    ..However, only controlled clinical trials will ultimately demonstrate whether prophylaxis can prevent joint bleeding and damage, and improve quality of life in patients with inhibitors...
  71. ncbi Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia
    Omer Aras
    Departments of Medicine Hematology, Oncology and Transplantation and Vascular Biology Center, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 103:4545-53. 2004
    ..MP-associated TF PCA was highly correlated with whole-blood TF PCA and total number of circulating MPs, and whole-blood TF PCA was highly correlated with TF mRNA levels...
  72. ncbi Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage
    Reinhard Lorenz
    Klinikum rechts der Isar, II Medizinische Klinik, Technische Universitat Munchen, Germany
    Eur J Gastroenterol Hepatol 15:15-20. 2003
    ..To evaluate the efficacy and safety of intravenous infusions of an improved prothrombin complex concentrate (PCC) formulation...
  73. ncbi Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation
    Hanno B Riess
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Thromb Res 121:9-16. 2007
    ..e. rapid correction of international normalized ratio (INR)...
  74. ncbi Factor VII Deficiency
    Guglielmo Mariani
    Dipartimento di Medicina Interna e Sanita Pubblica, Universita dell Aquila, L Aquila 67010, Italy
    Semin Thromb Hemost 35:400-6. 2009
    ..Several treatment options are available for FVII deficiency: the most effective are plasma-derived FVII concentrates and recombinant activated FVII (rFVIIa). Treatment-related side effects are rare...
  75. ncbi Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose
    Lorne Holland
    Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9073, USA
    Transfusion 49:1171-7. 2009
    ....
  76. ncbi Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16
    Andreas Fregin
    Institut für Humangenetik Universität Würzburg Biozentrum, Wurzburg, Germany
    Blood 100:3229-32. 2002
    ..Assuming that FMFD and warfarin resistance are allelic, conserved synteny between human and mouse linkage groups would restrict the candidate gene interval to the centromeric region of the short arm of chromosome 16...
  77. ncbi Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal
    Ingrid Pabinger
    Department of Internal Medicine, Division of Haematology and Haemostaseology, Medical University Vienna, Vienna, Austria
    Ann Hematol 89:309-16. 2010
    ..This study provides the first direct evidence that Beriplex P/N can be rapidly infused for emergency coumarin therapy reversal without altering safety or effectiveness...
  78. ncbi Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
    M Elg
    Department of Cardiovascular Pharmacology, AstraZeneca R and D, Molndal, Sweden
    Thromb Res 101:159-70. 2001
    ..Thus, stimulating thrombin generation with the use of APCC may counteract the anticoagulant effect observed with a very high dose of a thrombin inhibitor...
  79. ncbi Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity
    Eriko Shikata
    Department of Hospital Pharmacy, Faculty of Medicine, Tottori University, Yonago, Japan
    Blood 103:2630-5. 2004
    ....
  80. ncbi Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: a pilot study
    A Loktionov
    Medical Research Council, Dunn Clinical Nutrition Centre, Cambridge, UK
    Br J Nutr 79:133-9. 1998
    ..placebo on blood lipids and blood coagulation factors. Four ApoE genotype variants (seven E2/E3, forty-five E3/E3, twelve E3/E4 and one E4/E4) were found...
  81. pmc The impact of uncertainty in a blood coagulation model
    Christopher M Danforth
    Department of Mathematics and Statistics, Center for Complex Systems, Vermont Advanced Computing Center, University of Vermont, Burlington, VT 05401, USA
    Math Med Biol 26:323-36. 2009
    ....
  82. ncbi Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage
    Bernard Vigué
    Departement d Anesthesie Reanimation, AP HP, Centre Hospitalo Universitaire de Bicêtre, 78, rue du General Leclerc, 94275, Le Kremlin Bicetre Cedex, France
    Intensive Care Med 33:721-5. 2007
    ..We report the use of bolus infusions of PCC to immediately reverse anticoagulation and allow for urgent neurosurgical care...
  83. ncbi Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate
    Otis Warren
    Department of Emergency Medicine, Alameda County Medical Center, Oakland, CA 94612, USA
    Ann Emerg Med 53:758-61. 2009
    ..Thrombogenic complications of treatment with prothrombin complex concentrate have been reported before. Caution should be used when using prothrombin complex concentrates for reversal of anticoagulation...
  84. ncbi Perioperative hemostatic management of patients treated with vitamin K antagonists
    Jerrold H Levy
    Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322 1061, USA
    Anesthesiology 109:918-26. 2008
    ..Although many patients who require rapid reversal of warfarin are currently treated with fresh frozen plasma, PCCs should be considered as an alternative therapy...
  85. pmc Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate
    Herbert Schöchl
    Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Dr Franz Rehrl Platz 5, Salzburg, Austria
    Crit Care 14:R55. 2010
    ..The appropriate strategy for trauma-induced coagulopathy management is under debate. We report the treatment of major trauma using mainly coagulation factor concentrates...
  86. ncbi Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation
    Masahiro Yasaka
    Cerebrovascular Division, Department of Medicine, National Cardiovascular Center, 5 7 1 Fujishirodai, Suita, Osaka 565 8565, Japan
    Thromb Res 115:455-9. 2005
    ..0, but to be inadequate dose in patients with INR of 5.0 or more. PCC administration with vitamin K may finish reversing INR rapidly within 10 min and keep the reversed INR values for 12-24 h...
  87. ncbi Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts
    O A Fadeeva
    National Research Center for Hematology, Russian Academy of Medical Sciences, Moscow, Russia
    Biochemistry (Mosc) 75:734-43. 2010
    ..Investigation of the storage time has shown that activators containing immobilized tissue factor can be stored and used during for at least 100 days in the method studying spatial dynamics of fibrin clot formation...
  88. ncbi Laboratory, clinical and therapeutic aspects of acquired hemophilia A
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Italy
    Clin Chim Acta 395:14-8. 2008
    ..Moreover, we focus on the most recent advances in the treatment of this disorder, which is primarily aimed to control bleeding episodes and to eradicate the autoantibody production...
  89. ncbi Distinct structural and adhesive roles of Ca2+ in membrane binding of blood coagulation factors
    Y Zenmei Ohkubo
    Department of Biochemistry, Beckman Institute and Center for Biophysics and Computational Biology, University of Illinois at Urbana Champaign, Urbana, IL 61801, USA
    Structure 16:72-81. 2008
    ....
  90. ncbi Current opinion on inhibitor treatment options
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87113, USA
    Semin Hematol 43:S8-13. 2006
    ..Both the cost of therapy and the outcome of therapy will need to be considered in the development of future hemostatic agents for patients with inhibitors...
  91. pmc Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?
    Karim Brohi
    Department of Surgery, University of California at San Francisco, San Francisco, CA, USA
    Ann Surg 245:812-8. 2007
    ..We hypothesized that early coagulopathy is due to tissue hypoperfusion, and investigated derangements in coagulation associated with this...
  92. ncbi Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study
    Lloyd E Chambless
    Department of Biostatistics, University of North Carolina, CB 8300, 137 East Franklin Street, Suite 400, Bank of America Center, Chapel Hill, NC 27514 4145, USA
    J Clin Epidemiol 56:880-90. 2003
    ..These factors substantially improved prediction of future CHD for men, less for women, and also increased attributable risks...
  93. ncbi Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes
    Alan L Parker
    British Heart Foundation Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, 126 University Place, University of Glasgow, G12 8TA, United Kingdom
    Blood 108:2554-61. 2006
    ..Our results indicate a common and pivotal role for distinct vitamin K-dependent coagulation factors in mediating hepatocyte transduction by adenoviruses in vitro and in vivo...
  94. ncbi Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
    Ross I Baker
    Thrombosis and Haemophilia Service, Royal Perth Hospital, Perth, WA, Australia
    Med J Aust 181:492-7. 2004
    ..5 and surgery can be conducted safely. Bridging anticoagulation therapy for patients at high risk for thromboembolism should be undertaken in consultation with the relevant experts...
  95. ncbi Plasma microparticles and vascular disorders
    Susan F Lynch
    College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK
    Br J Haematol 137:36-48. 2007
    ..Knowledge of the functional properties of microparticles will contribute to our understanding of the mechanisms underlying vascular dysfunction and prothrombotic states...
  96. ncbi Postoperative bypass bleeding: a bypass-associated dilutional (BAD) coagulopathy?
    Brian S Bull
    School of Medicine, Department of Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA 92350, USA
    Blood Cells Mol Dis 43:256-9. 2009
    ..The presence of un-neutralized protamine combined with critically lowered clotting factors leads to marked coagulopathy...
  97. ncbi Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    L M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Thromb Haemost 2:1700-8. 2004
    ..Nevertheless, this comprehensive pharmacovigilance assessment does not support superior thrombotic safety of rFVIIa and suggests that thrombotic AE risk may be higher in rFVIIa than FEIBA recipients...
  98. ncbi Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
    G A Allen
    Department of Pediatrics Department of Pathology and Laboratory Medicine Department of Medicine Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, NC, USA
    J Thromb Haemost 2:402-13. 2004
    ....
  99. ncbi Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    J Trauma 68:1151-7. 2010
    ..Multicomponent therapy with prothrombin complex concentrate (PCC) containing coagulation factors II, VII, IX, and X might offer potential advantages...
  100. ncbi Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation
    Aaron Lubetsky
    Institute of Thrombosis and Haemostasis, Sheba Medical Center, Tel Hashomer, Israel
    Thromb Res 113:371-8. 2004
    ..We conclude that Octaplex is effective and safe in situations where rapid reversal of anticoagulation is needed...
  101. ncbi Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model
    Ingo Pragst
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Thromb Res 125:272-7. 2010
    ....

Research Grants66

  1. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    Thomas Ortel; Fiscal Year: 2010
    ..RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..
  2. Regulation of factor VIII Levels and Activity by Members of LDL Receptor Family
    Dudley K Strickland; Fiscal Year: 2013
    ....
  3. Harness Germinal Matrix Hemorrhage
    John H Zhang; Fiscal Year: 2013
    ..The long-term goals of this proposal are to provide non-invasive therapeutic approaches for GMH patients. ..
  4. Mechanisms of vascular-specific gene regulation by estrogen
    Gavin R Schnitzler; Fiscal Year: 2013
    ..abstract_text> ..
  5. Molecular Basis for Priming of the Neutrophil NADPH Oxidase in Trauma and Sepsis
    ALBERT T HSU; Fiscal Year: 2010
    ..In regards to public health, the overall goal of this research project is to reduce morbidity and mortality from MOSF in Surgical Intensive Care Units. ..
  6. Structural and Biochemical Basis of the Vitamin K cycle
    Weikai Li; Fiscal Year: 2013
    ..Future research in my group will use a combination of X-ray crystallography, protein biochemistry, and cell biology. My long-term goal is to understand the entire vitamin K pathway that sustains blood coagulation. ..
  7. Recombinant and Chemo-/Bio-Orthogonal Synthesis of Liposomal Thrombomodulin
    Xue Long Sun; Fiscal Year: 2013
    ....
  8. Membrane Receptors Regulating Megakaryocyte Endocytosis of Factor V from Plasma
    BETH BOUCHARD; Fiscal Year: 2012
    ..End of Abstract) ..
  9. Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD Risk
    David C Glahn; Fiscal Year: 2013
    ..The results of this project should identify causal genes underlying CVD risk. Identification of the causal genes will obligately generate on the pathways of these genes and will directly identify novel drug targets. ..
  10. Targeted Delivery of a Novel Synthetic Curcumin Analog, EF24 to Glioblastoma and
    MAMORU NONE SHOJI; Fiscal Year: 2012
    ....
  11. Therapeutic-Expression of a Platelet-Specific Integrin
    DAVID ALLEN WILCOX; Fiscal Year: 2010
    ..This study should lead to the development of safe and effective methods for human gene therapy for inherited platelet bleeding disorders and other diseases of hemostasis. ..
  12. A diagnostic instrument to manage hemostasis in chronic liver disease
    Francesco Viola; Fiscal Year: 2012
    ....
  13. Factor XI inhibitor for thrombosis
    ERIK IAN TUCKER; Fiscal Year: 2013
    ....
  14. Therapeutic factor XI blockade for sepsis
    ERIK IAN contact TUCKER; Fiscal Year: 2010
    ..We address this major medical need with a new antithrombotic antibody product candidate to provide a safe and effective alternative to APC. ..
  15. Self-Complementary AAV2 Factor IX for Hemophilia B
    SCOTT WILLIAM JOHN MCPHEE; Fiscal Year: 2010
    ..Reduced patient burden, non-compliance, and exposure to blood products are expected to correlate with reductions in morbidity and mortality - as well as a vastly improved quality of life for Hemophilia B patients in the U.S. alone. ..
  16. Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy
    Sergei Zolotukhin; Fiscal Year: 2013
    ....
  17. Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT)
    ANGARA KONETI RAO; Fiscal Year: 2013
    ....
  18. Structure and Stability Studies of Factor VIII to Overcome the Immune Response
    PAUL CLINTON SPIEGEL; Fiscal Year: 2010
    ..Studying the structural basis of antibody recognition of factor VIII as well as using protein engineering to improve the stability of factor VIII may lead to improved therapies for hemophiliacs worldwide. ..
  19. Antithrombotic Aptamers and Antidotes
    BRUCE ALAN SULLENGER; Fiscal Year: 2013
    ..We believe the generation of such antidote controllable therapeutic agents will lead to safer treatment of a number of cardiovascular disorders and improve the overall health and welfare of the public. ..
  20. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2012
    ..Results to date have produced a patent for an improved coagulation factor assay and are expected to yield drugs/procedures for managing coagulation in a clinical setting. ..
  21. Development of a novel production platform for complex recombinant biotherapeutic
    JOHN S LOLLAR; Fiscal Year: 2012
    ..The studies proposed herein are designed to provide proof-of-concept of the efficiency and scalability, as well as, rigorous preclinical validation and characterization of this novel manufacturing platform. ..
  22. Characterization of coagulation factor-platelet interactions: role of FXI
    Owen J McCarty; Fiscal Year: 2013
    ..We propose that elucidation of the role that FXI plays in clot formation may provide the basis for the pharmaceutical development of such a novel class of FXI-targeted anti-thrombotics. ..
  23. The Role of Adipose Tissue in Age-dependent Sensitivity to Critical Illness
    Hiroshi Saito; Fiscal Year: 2013
    ..These studies will provide significant insight into the association of the previously neglected adipose organ in aging and critical illness. ..
  24. PROTEIN Z DEPENDENT PROTEINASE INHIBITOR
    George J Broze; Fiscal Year: 2011
    ..The work will provide important information that will enhance our understanding of the regulation of coagulation by PZ and ZPI and its role in human thrombotic disease. ..
  25. Thromboregulatory strategies to prolong xenograft survival.
    Simon Robson; Fiscal Year: 2009
    ..These studies will be judged successful if novel, clinically relevant antithrombotic therapies can be then developed and applied. ..
  26. Molecular interactions between soluable host factors and a gene delivery vector
    Vijay S Reddy; Fiscal Year: 2013
    ..Recently, it has been shown that association of species A and C HAdVs with several blood coagulation factors (e.g...
  27. Factor XI Inhibition for the Treatment of Ischemic Stroke
    ERIK IAN TUCKER; Fiscal Year: 2012
    ..Since 14E11 is not expected to produce bleeding side-effects, this approach has the potential to provide a safe alternative or addition to other more dangerous antithrombotic treatments. ..
  28. Hemostatic Factors as Determinants of Bacterial Virulence and Host Defense.
    Jay L Degen; Fiscal Year: 2010
    ....
  29. AAV-Mediated Gene Therapy for Hemophilia
    Andrew M Davidoff; Fiscal Year: 2013
    ..In addition, results from these studies will be of great utility not only for hemophilia A gene therapy but also other disorders that are potentially amenable to AAV-mediated, liver-targeted gene transfer. ..
  30. Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated Vasculitis
    Peter A Merkel; Fiscal Year: 2011
    ..This application seeks funding to support 5 study sties in the United States and combine resources with funding from the United Kingdom. ..
  31. ER-to-Golgi transport of coagulation factors V and VIII
    Bin Zhang; Fiscal Year: 2013
    ..will study a transport receptor that when absent, cause a human genetic disorder with low levels of blood coagulation factors V and VIII...
  32. Development of a point of care diagnostic to guide efficient usage of blood produ
    Francesco Viola; Fiscal Year: 2013
    ..This research is a collaborative effort between HemoSonics, the University of Virginia Department of Biomedical Engineering and School of Medicine, and Medical College of Virginia (Virginia Commonwealth University). ..
  33. Functional Implications of VWF A1 Domain Polymorphisms
    Veronica H Flood; Fiscal Year: 2013
    ....
  34. Protease activated receptor-1 signaling by protein C
    Matthias Riewald; Fiscal Year: 2012
    ..The results will have important implications for novel treatment strategies for diseases where the inflammatory response plays a key role, including myocardial infarction and stroke. ..
  35. Pharmacogenetics in Rural and Underserved Populations
    Kenneth E Thummel; Fiscal Year: 2013
    ....
  36. INTERACTION OF PLATELETS WITH COAGULATION FACTORS IX & X
    Peter Walsh; Fiscal Year: 1992
    ..These studies will provide essential information about the role of platelets in promoting the assembly of enzyme-cofactor-substrate complexes and the proteolytic activation of coagulation zymogens...
  37. Thrombin-mediated proteolysis in neuroinflammatory disease
    Jay L Degen; Fiscal Year: 2012
    ..The goal of this research is to use modern molecular genetics to develop a more detailed mechanistic understanding of the role of key coagulation factors in neuroinflammatory disease and identify novel therapeutic opportunities. ..
  38. Prevention of the Complications of Bleeding Disorders Through HTCS
    Regina Butler; Fiscal Year: 2010
    ....
  39. Gene Transfer for Galactosialidosis - Resub
    Arthur W Nienhuis; Fiscal Year: 2013
    ..The tril will be monitored for evidence of gene transfer, for biochemical evidence of PPCA production and for correction of the clinical manifestations of the disorder. ..
  40. Manufacturing Process Development for Bioengineered FVIII
    JOHN S LOLLAR; Fiscal Year: 2013
    ....
  41. The Role of Tissue Factor: FVIIa-PAR-2 Signaling in Heart Ischemia/Reperfusion
    RAFAL L PAWLINSKI; Fiscal Year: 2013
    ..Understanding the role of TF:FVIIa-dependent activation of PAR-2 in injured heart may lead to the development of new therapies to reduce myocardial infarction and heart failure. ..
  42. CELLULAR REGULATION OF BLOOD CLOTTING
    Marc Shuman; Fiscal Year: 1992
    ..c) to identify and characterize other antigens involved in immune disorders of platelets...
  43. MOLECULAR INTERACTIONS OF BLOOD COAGULATION FACTOR XA
    Katherine High; Fiscal Year: 1999
    ..This work will contribute to our understanding of the molecular interactions by which F.Xa exerts its biological effects in enzyme complexes and through cellular receptors. ..
  44. Structure & Function of the Gamma-Glutamyl Carboxylase
    Darrel W Stafford; Fiscal Year: 2011
    ....
  45. MOLECULAR INTERACTIONS OF BLOOD COAGULATION FACTOR X
    RICHARD PAINTER; Fiscal Year: 1991
    ..Identification of sites of interactions on factor X/Xa may lead to the production of therapeutic agents (peptides and/or monoclonal antibodies) which can impede coagulation and regulate hemostasis...
  46. Structural Mechanisms for the Inhibition of Thrombosis
    JAMES HUNTINGTON; Fiscal Year: 2009
    ....
  47. Structure, Function &Genetics of Coagulation Factors
    Darrel W Stafford; Fiscal Year: 2013
    ..The individual projects fit together naturally and the synergism between the projects themselves is enhanced by the synergism that has developed between the investigators involved in the program. ..
  48. Biosynthesis of N-linked Glycoproteins: Two Fates - Folding or Degradation
    William J Lennarz; Fiscal Year: 2010
    ....
  49. Mechanisms of Clotting Factor Assembly
    James H Morrissey; Fiscal Year: 2013
    ..They are also designed to develop novel hemostatic agents for treating bleeding. ..
  50. Improving safety and efficacy of gene therapy with HDAd
    Philip Ng; Fiscal Year: 2013
    ..Specific Aim 3 is to determine the safety and efficacy of delivering a helper-dependent adenoviral vector expressing canine coagulation factor IX by the balloon method into FIX-deficient dogs as a model for hemophilia B gene therapy. ..
  51. Biological Vascular Grafts
    Laura E Niklason; Fiscal Year: 2013
    ....
  52. SIGNAL PEPTIDASE STRUCTURE AND FUNCTION
    MARK LIVELY; Fiscal Year: 1999
    ..Achievement of this goal will permit precise determination of the mechanism of action of this unusual membrane- bound proteinase. ..
  53. Functional Domains of Coagulation Factor V
    Michael Kalafatis; Fiscal Year: 2007
    ..We have established a system to study phospholipids-driven macromolecular complex formation, which may be a model for the generation of complexes that form extra-and intra-cellularly. ..
  54. Tyrosine Sulfation and Chemokine Receptor Function
    Kevin Moore; Fiscal Year: 2006
    ..These studies will provide new insights into the importance of tyrosine sulfation in innate and adaptive host responses during a wide variety of pathophysiological processes. ..
  55. PROXIMAL TUBULE ANGIOTENSINS--HEMOLYTIC UREMIC SYNDROME
    Julie Ingelfinger; Fiscal Year: 2004
    ..It is anticipated that specific blockade may lead to strategies with clinical relevance for the possible prevention or amelioration of HUS. ..
  56. VITAMIN K-DEPENDENT PROTEINS IN LIVER & ISOLATED CELLS
    Reidar Wallin; Fiscal Year: 1992
    ..Special emphasis is placed on the biosynthesis of blood coagulation factors. A major part of the proposed work focusses on an endonuclease eta (endo eta) insensitive protein that ..
  57. COMMON VARIANTS IN CANDIDATE GENES AND PREMATURE MI RISK
    Stephen Schwartz; Fiscal Year: 2001
    ....
  58. DEFINITION OF FUNCTIONAL SITES ON COAGULATION FACTOR X
    WILLIAM CHURCH; Fiscal Year: 1993
    ....
  59. Novel Reagents to Bypass Limitations of Existing Coagulation Assays
    Stephen Burgess; Fiscal Year: 2009
    ..If effective, this will decrease misdiagnoses of bleeding disorders and will remove the need for expensive subsequent testing. ..
  60. ROLE OF FACTOR XIII BINDING TO THE HEMOSTATIC PLUG
    Charles Greenberg; Fiscal Year: 1993
    ..Results from these studies may have direct application to the development of diagnostic and therapeutic agents which could benefit several thrombotic disorders including myocardial infraction, stroke and pulmonary embolization...
  61. Immune Responses To AAV-Mediated FIX Gene Transfer
    Hildegund C J Ertl; Fiscal Year: 2013
    ..HC ErtI): T Cells to AAV and AAV-Encoded Transgene Products Project 3 (RW Herzog, C Terliorst): Pathways Towards Immune Tolerance to Coagulation Factors Core A (HC ErtI): Administrative Core Core B (S Zliou): Vector Core ..
  62. Bioprocessing of Plasma Therapeutic Proteins using Sequential Affinity Monolithic
    Yow Pin Lim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  63. MEMBRANE BIOPHYSICS AND CONTROL OF THROMBIN GENERATION
    BARRY LENTZ; Fiscal Year: 1999
    ..DESCRIPTION: This ongoing project proposes to extend studies of the role(s) of PS allosteric regulation of blood coagulation factors Xa and Va...
  64. Functional Cooperation of Tissue Factor and Integrins
    Wolfram Ruf; Fiscal Year: 2013
    ..The proposed studies are expected to yield valuable new insights into potential therapeutic approaches to block tumor promoting signaling of the coagulation pathway. ..
  65. Factor Va regulation of prothrombinase activity
    JAMILA HIRBAWI; Fiscal Year: 2010
    ..Proteins will be screened for clotting activity in one-and two-stage clotting assays. Kinetic analyses will be done by measuring thrombin formation. ..
  66. EPITOPES OF ANTIFACTOR VIII ANTIBODIES IN HEMOPHILIACS
    Dorothea Scandella; Fiscal Year: 1999
    ..The presence of new antibodies in tolerant patients has been previously reported but their relationship to the tolerant state was not elucidated. ..